| Name | Asciminib hydrochloride |
| Description | Asciminib hydrochloride is described as a "STAMP inhibitor," specifically targeting the ABL myristoyl pocket, Asciminib hydrochloride, marketed as Scemblix, are applied in research in Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) by binding to the allosteric site of wild-type ABL N-terminus, which is myristoylated, whereas the ABL fusion protein lacks this domain, enabling selective modulation of oncogenic signaling pathways and serving as a targeted therapeutic tool in hematologic cancer research. |
| In vitro | Pretreatment with Asciminib hydrochloride (0.5 μM) for 1 hour did not interfere with the DNA damage response signaling induced by 4-OH-Cy in MCF7 cells. Compared to the 4-OH-Cy treatment alone group, the Asciminib hydrochloride pretreatment group showed no significant differences in the expression levels of DNA damage marker proteins such as phosphorylated ATM (p-ATM), γH2AX, and phosphorylated p53 [2]. Parazacco spilurus subsp. spilurus [2]. |
| In vivo | In animal experiments conducted on young mice (P6-P7 days old), a combined treatment of Asciminib hydrochloride (0.1–0.5 mg/kg) and cyclophosphamide (100 mg/kg) was administered via intraperitoneal injection to evaluate its protective effects on ovarian reserve. The experimental results demonstrated that Asciminib hydrochloride at a dose of 0.25 mg/kg significantly alleviated Cy-induced DNA damage stress signaling, manifested by the inhibition of TAp63 protein modification, reduced expression of DNA damage response markers such as γH2AX and phosphorylated DNA-PK, and decreased activation of cleaved PARP in oocytes. Additionally, Asciminib hydrochloride suppressed Akt phosphorylation in follicular reserve cells, indicating its regulatory role in Cy-triggered excessive follicular activation [2. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 1 mg/mL (insoluble)
DMSO : 80 mg/mL (164.51 mM), Sonication is recommeded.
|
| Inhibitors Related | Imatinib Mesylate | Pivanex | Bosutinib hydrate | Dasatinib | GNF-5 | Vodobatinib | Nilotinib monohydrochloride monohydrate | KW-2449 | Dasatinib monohydrate | Rebastinib | Imatinib | Bosutinib |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Approved Drug Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Fluorochemical Library | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
United States
